
Evolving Models of HIV Care
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Meeting Slides

Clinical Practice Guidelines
Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy.
World Health Organization, 2017.
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV.
US Department of Health and Human Services, 2017 (last updated March 2019).
HIV Testing Guidelines.
Centers for Disease Control and Prevention (CDC), 2018.
Clinical Resources
90–90–90: An Ambitious Treatment Target to Help End the AIDS Epidemic.
Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014.
AIDSVu.
Emory University Rollins School of Public Health, Gilead Sciences, Inc., and the Center for AIDS Research at Emory University (CFAF), 2018.
AtlasPlus Presentation Slides: HIV Diagnoses by County, 2014.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
Database of Antiretroviral Drug Interactions.
HIV InSite. University of California, San Francisco, 2018.
Harm Reduction Coalition.
HEP Drug Interactions.
University of Liverpool, last reviewed March 2019.
Status of State Medicaid Expansion Decisions: Interactive Map.
Kaiser Family Foundation, 2019.
Suggested Readings
Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial.
Amanyire G, et al. Lancet HIV. 2016;3(11):e539-e548.
RAPID ART: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population.
Coffey S, et al. AIDS. 2018. [Epub ahead of print]
Antiretroviral therapy for the prevention of HIV-1 transmission.
Cohen MS, et al. N Engl J Med. 2016;375(9):830-839.
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen MS, et al. N Engl J Med. 2011;365(6):493-505.
A rapid entry program in the South: improving access to care and time to viral suppression.
Colasanti J, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI) 2018; March 4−7, 2018; Boston, MA. Poster 1109.
Continuous retention and viral suppression provide further insights into the HIV care continuum compared to the cross-sectional HIV care cascade.
Colasanti J, et al. Clin Infect Dis. 2016;62(5):648-654.
HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable.
Eisinger RW, et al. JAMA. 2019;321(5):451-452.
Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans.
Halperin J, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
Rapid HIV care cuts time to viral suppression in half.
Schoen J, Gallagher G. Healio Infect Dis News. 2018.
Initiation of antiretroviral therapy in early asymptomatic HIV infection.
INSIGHT START Study Group. N Engl J Med. 2015;373(9):795-807.
Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial.
Koenig SP, et al. PLoS Med. 2017;14(7):e1002357.
Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trial.
Labhardt ND, et al. JAMA. 2018;319(11):1103-1112.
Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa.
Petersen M, et al. JAMA. 2017;317(21):2196-2206.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a U.S. public health setting.
Pilcher CD, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial.
Rosen S, et al. PLoS Med. 2016;13(5):e1002015.
Trends in the San Francisco human immunodeficiency virus epidemic in the "Getting to Zero" era.
Scheer S, et al. Clin Infect Dis. 2018;66(7):1027-1034.
A trial of early antiretrovirals and isoniazid preventive therapy in Africa.
TEMPRANO ANRS 12136 Study Group. N Engl J Med. 2015;373(9):808-822.
Pooled week 48 efficacy and baseline resistance: B/F/TAF in treatment-naïve patients.
White K, et al. CROI 2018. March 4−7, 2018; Boston, MA. Abstract 532.
Patient Resources
Centers for Disease Control and Prevention (CDC): HIV Basics
The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This comprehensive site provides extensive links to topics across the HIV-care continuum, including PrEP.
Project Inform
Project Inform provides up-to-date information to help people living with HIV and HCV make the best choices regarding their treatment and care.
Hepatitis C and HIV Co-infection Booklets
Sex-C: Sex and Hepatitis C Prevention Tips for Gay Men
Sexual Transmission of Hepatitis C: A Guide for HIV-Positive Gay Men
Positively Aware
Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for MSM and transgender people.
Smartphone Pill-Reminder Apps (Free)
Mango Health — Medicine Reminder and Manager for iPhone
Mango Health for Android
Medisafe Pill Reminder and Alarm for iPhone
Medisafe Pill Reminder and Medication Tracker for Android
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCPs Role in Preventing HIV
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies